Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics Following Different Dosing Regimens of MK-8266 or Placebo in Subjects With Hypertension
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2014
At a glance
- Drugs MK 8266 (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 15 Mar 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
- 15 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Feb 2011 Planned End Date changed from 1 Apr 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.